The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Fibroblast Growth Factor 21 Limits Lipotoxicity by Promoting Hepatic Fatty Acid Activation in Mice on Methionine and Choline-Deficient Diets
Open accessAbstract
Background & aims Nonalcoholic fatty liver disease is a common consequence of human and rodent obesity. Disruptions in lipid metabolism lead to accumulation of triglycerides and fatty acids, which can promote inflammation and fibrosis and lead to nonalcoholic steatohepatitis. Circulating levels of fibroblast growth factor (FGF)21 increase in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis; therefore, we assessed the role of FGF21 in the progression of murine fatty liver disease, independent of obesity, caused by methionine and choline deficiency.Methods C57BL/6 wild-type and FGF21-knockout (FGF21-KO) mice were placed on methionine- and choline-deficient (MCD), high-fat, or control diets for 8-16 weeks. Mice were weighed, and serum and liver tissues were collected and analyzed for histology, levels of malondialdehyde and liver enzymes, gene expression, and lipid content.Results The MCD diet increased hepatic levels of FGF21 messenger RNA more than 50-fold and serum levels 16-fold, compared with the control diet. FGF21-KO mice had more severe steatosis, fibrosis, inflammation, and peroxidative damage than wild-type C57BL/6 mice. FGF21-KO mice had reduced hepatic fatty acid activation and β-oxidation, resulting in increased levels of free fatty acid. FGF21-KO mice given continuous subcutaneous infusions of FGF21 for 4 weeks while on an MCD diet had reduced steatosis and peroxidative damage, compared with mice not receiving FGF21. The expression of genes that regulate inflammation and fibrosis were reduced in FGF21-KO mice given FGF21, similar to those of wild-type mice.Conclusions FGF21 regulates fatty acid activation and oxidation in livers of mice. In the absence of FGF21, accumulation of inactivated fatty acids results in lipotoxic damage and increased steatosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Altogether, FGF21 seems to serve as a protective factor that limits hepatic toxicity [141,167] and dysfunction [168].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [167]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
FGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125
Pathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809
Lipid Droplets and Cellular Lipid Metabolism
Walther, T. C., & Farese, R. V. (2012) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061009-102430 · Cited by 1,701
Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495
FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis
Fisher, F. M., Kleiner, S., Douris, N., Fox, E. C., Mepani, R. J., Verdeguer, F., Wu, J., Kharitonenkov, A., Flier, J. S., Maratos-Flier, E., et al. (2012) · Genes & Development · doi:10.1101/gad.177857.111 · Cited by 1,478
Xu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077
Flagged first, then by citations
1 of the 44 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–264 of 264
Chen, W., Shen, Z., Cai, S., Chen, L., & Wang, D. (2021) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/133494 · Cited by 8
Amirkhizi, F., Taghizadeh, M., Khalese-Ranjbar, B., Shahraki, S. H., & Asghari, S. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03613-8 · Cited by 7
Association Between Serum Afamin Levels with Nonalcoholic Associated Fatty Liver Disease
Chen, S., Liu, Z., Li, C., Wang, J., Zhang, J., Zhang, X., & Xu, C. (2022) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2022/7175108 · Cited by 7
Fibroblast growth factor 21 ameliorates cholestatic liver injury via a hepatic FGFR4-JNK pathway
Zhou, C., Pan, X., Huang, L., Wu, T., Zhao, T., Qi, J., Wu, J., Mukondiwa, A. V., Tang, Y., Luo, Y., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166870 · Cited by 7
The emerging role of fibroblast growth factor 21 in diabetic nephropathy
Mao, S., Ren, X., & Zhang, J. (2016) · Journal of Receptors and Signal Transduction · doi:10.3109/10799893.2016.1147582 · Cited by 7
Sleeve gastrectomy attenuates high fat diet-induced non-alcoholic fatty liver disease
Pei, E., Liu, Y., Jiang, W., Lin, S., Huang, L., Lin, M., & Cai, L. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0875-5 · Cited by 7
Xu, Y., & Lu, Y. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.05.099 · Cited by 6
FGF21 protects against ischaemia reperfusion injury in normal and fatty livers
Ma, Y., Singhal, G., Chan, S., Wang, C., Yu, H., Yin, B., Pang, J., Malvar, G. L., Nasser, I. A., Mather, M. L., et al. (2024) · Liver International · doi:10.1111/liv.15911 · Cited by 6
FGF21-dependent alleviation of cholestasis-induced liver fibrosis by sodium butyrate
Yang, J., Chen, L., Zhao, S.-S., Du, C., Fan, Y.-Z., Liu, H., Li, Y., & Li, Y.-Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1422770 · Cited by 7
Olivares, S., & Henkel, A. S. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.09.006 · Cited by 6
Korkmaz, D., Konya, P. Ş., & Demirtürk, N. (2022) · Turkish Journal of Parasitology · doi:10.4274/tpd.galenos.2022.14633 · Cited by 5
The liver-bone axis: an emerging player in disease pathogenesis and therapeutic intervention
Han, S., Wei, Y., Yu, G., Jia, W., Liao, W., He, Y., Cheng, K., Zhao, J., Xiang, S., Zhang, W., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3207-5 · Cited by 5
Rama, K., Jahagirdar, V., & Sanyal, A. J. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s560034 · Cited by 6
Treating metabolic dysfunction‐associated steatohepatitis: The fat‐trimming FGF21 approach
Li, X., Rao, Z., Hu, W., Lu, W., & Luo, Y. (2024) · Obesity Reviews · doi:10.1111/obr.13861 · Cited by 6
Liu, W., Guo, X.-Z., Chen, Y., Tang, Y.-Q., Xiao, H., Wang, Y., Li, S.-M., & Zhou, Z.-G. (2022) · Aquaculture Reports · doi:10.1016/j.aqrep.2022.101096 · Cited by 4
Fibroblast growth factor 21 signaling: The liver in focus
Mahlapuu, M., & Marschall, H. (2016) · Hepatology · doi:10.1002/hep.28591 · Cited by 5
Huang, Y., Liu, B., Hu, C., & Lu, Y. (2025) · Protein & Cell · doi:10.1093/procel/pwaf027 · Cited by 4
The hallmarks of protein and amino acid restriction in aging and longevity
Knopf, B. A., & Lamming, D. W. (2026) · Cell Press Blue · doi:10.1016/j.cpblue.2026.100079 · Cited by 4
Insights into the role of FGF21 in coronary heart disease
Zhang, Q.-Y., & Liu, H. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.136911 · Cited by 4
Bibliometric analysis of fibroblast growth factor 21 research over the period 2000 to 2021
She, Q.-Y., Li, L., Liu, M.-H., Tan, R.-Y., Zhong, Y.-W., Bao, J., & Xie, J.-D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1011008 · Cited by 9
Dinerman, S., & Shu, Y. (2025) · International Journal of Translational Medicine · doi:10.3390/ijtm5010007 · Cited by 4
Nuclear Receptors in Energy Metabolism
Walth-Hummel, A. A., Herzig, S., & Rohm, M. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-11836-4_4 · Cited by 4
Qi, J., Guo, Z., Zhu, S., Jiang, X. J., Wu, Y., Chen, Y., Hu, F., Xiong, J., Wu, Y., Ye, X., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.129797 · Cited by 3
Stevanović, D., Hebert, A. J., Desai, B. N., Singhal, G., Adams, A. C., Flier, J. S., & Maratos–Flier, E. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.01.27.921361 · Cited by 3
Chen, Z., Liu, T., Huang, P., Liu, Y., Xu, S., Ding, J., Song, H., Yang, L., & Zheng, P. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177874 · Cited by 2
Oral gene delivery platform based on glycol chitosan-PEG-lactoferrin conjugate
Jang, S., Priscilla, L., Lee, C. W., Lee, S. A., Lee, M., & Lee, D. Y. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114463 · Cited by 2
Fanti, M., Brandhorst, S., Navarrete, G., Diaz, A., Giuliani, G., Chowdhury, D., Antunes, G. C., Morgan, T. E., Dubeau, L., Villani, V., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.05.015 · Cited by 4
Receptor Tyrosine Kinases and the Insulin Signaling System
White, M. F. (2018) · Endocrinology · doi:10.1007/978-3-319-44675-2_7 · Cited by 2
Ruiz-Padilla, A. J., Ruíz‐Noa, Y., Ibarra‐Reynoso, L. D. R., Lazo-de-la-Vega-Monroy, M.-L., Alonso‐Castro, Á. J., Sánchez-Barajas, M., Alvarez-Alvarez, R. M., & Preciado‐Puga, M. D. C. (2020) · Current HIV Research · doi:10.2174/1570162x18666200719235625 · Cited by 2
Li, X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15793-6.00003-2 · Cited by 2
Kim, J., Chang, N., Kim, Y.-K., Lee, J., Oh, D., Choi, J., Kim, O., Kim, S., Choi, M., Lee, J., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16111601 · Cited by 1
Wang, J.-M., Jiang, L.-Y., Deng, Y.-T., Li, J.-Y., Sun, H., Ran, L., & Xiao, X. (2026) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005638 · Cited by 1
Shmidov, Y., Sirohi, P., Su, J. C., Tong, J. (., Suresh, R., Milligan, J. J., Shapiro, D. M., & Chilkoti, A. (2026) · ACS Synthetic Biology · doi:10.1021/acssynbio.6c00115 · Cited by 1
Hepatocyte-specific deletion of Pparα promotes NASH in the context of obesityPreprint
Régnier, M., Polizzi, A., Smati, S., Lukowicz, C., Fougerat, A., Lippi, Y., Fouché, E., Lasserre, F., Naylies, C., Bétoulières, C., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/488031 · Cited by 1
Kwon, R.-W., Lee, S., Kim, T.-W., & Lee, J. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.18.469147 · Cited by 1
Cheng, T. W., & Leung, P. S. (2017) · Springer eBooks · doi:10.1007/978-3-319-67199-4_101992 · Cited by 1
Liu, C., Schönke, M., Spoorenberg, B., Lambooij, J. M., van der Zande, H. J. P., Zhou, E., Tushuizen, M. E., Andréasson, A., Park, A., Oldham, S. N., et al. (2023) · eLife · doi:10.7554/elife.83075.sa2 · Cited by 1
Current and Emerging Therapies for Nonalcoholic Fatty Liver Disease
Gawrieh, S., & Chalasani, N. (2015) · Springer eBooks · doi:10.1007/978-3-319-20538-0_16
The role of hepatic aryl hydrocarbon receptor in metabolic homeostasis and hepatic carcinogenesis
Lu, P. (2016) · D-Scholarship@Pitt (University of Pittsburgh)
Receptor Tyrosine Kinases and the Insulin Signaling System
White, M. F. (2017) · Endocrinology · doi:10.1007/978-3-319-27318-1_7-1
The Role Of Crebh In Hepatic Energy Regulation Under Metabolic Stress
Mendez, R. (2015) · Human Biology
Restriction of essential amino acids dictates the systemic response to dietary protein dilutionPreprint
Yap, Y. W., Rusu, P. M., Chan, A. Y., Fam, B. C., Jungmann, A., Solon‐Biet, S. M., Barlow, C. K., Creek, D. J., Huang, C., Schittenhelm, R. B., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/848143
Bayoumi, A. (2020) · The Sydney eScholarship Repository (The University of Sydney)
Kamimura, H., Kimura, A., & Terai, S. (2021) · Internal Medicine · doi:10.2169/internalmedicine.6906-20
Utilization of fault tree analysis techniques in fire protection work
Crass, E. R. (1986) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)
Kurtdede, E., Kara, E., Elifoğlu, T. B., & Kaya, U. (2021) · Eurasian journal of veterinary sciences · doi:10.15312/eurasianjvetsci.2021.350
Cheng, T. W., & Leung, P. S. (2017) · Springer eBooks · doi:10.1007/978-1-4614-6438-9_101992-1
Lü, C., Jin, L., Bi, J., Jin, H., You, X., Peng, L., Wang, L., Fan, Z., & Wang, X. (2023) · Research Square · doi:10.21203/rs.3.rs-2441482/v1
Lü, C., Jin, L., Bi, J., Jin, H., You, X., Peng, L., Fan, H., Wang, H., Wang, L., Fan, Z., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1176136
Li, X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15793-6.00000-7
Feng, J. N., Tong, Q., & Jin, T. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100602
Olajuyin, A., Elferink, C., & Wright, C. W. (2025) · Discover medicine · doi:10.1007/s44337-025-00364-z
Afrisham, R., Sadegh‐Nejadi, S., Meshkani, R., Emamgholipour, S., & Paknejad, M. (2020) · Figshare · doi:10.6084/m9.figshare.12133713
Xiao, Y.-J., Liu, X.-P., Zhang, Y.-L., Cheng, Y., Tian, X., Liu, Y.-Q., Deng, C.-L., & Sun, H. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1731065
Homéostasie des céramides et hépatopathies métaboliques
Régnier, M. (2018) · theses.fr (ABES) · doi:10.70675/2fb92711z373cz4b27z8082z7aa3f8930e63
Drug Development for MASH ‐Related Compensated Cirrhosis: Past, Present and Future
Zeng, R., Shao, Y. C., Lin, R.-T., Shen, X.-T., Sun, Q., Xin, X., Liu, P., Fan, J., Hu, Y., & Feng, Q. (2026) · Liver International · doi:10.1111/liv.70784
Fermented Milk as an Alternative Therapy for Obesity
Safitri, U., Rustanti, N., Pramono, A., & Suparmi, S. (2026) · International Journal of Food Science · doi:10.1155/ijfo/5584818
Adipokine in Metabolic Liver Disease: Adipo–Brain–Liver Cross talk
苏喻乐, Yang, Y., Sun, W., Yu, Z., Wang, Y., 刘世新, Chen, Z., Li, Y., Yang, X., Liu, J., et al. (2026) · International Journal of Endocrinology · doi:10.1155/ije/9009628
Beneficial Hepatokines in MASLD/MASH: Therapeutic Potentials and Drug Delivery Challenges
Amatya, R., Min, K. A., & Shin, M. C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167118
Research Advances in the FGFR Signaling Axis in Hepatic Fibrosis
万, 良. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.16103343
Lucaciu, R. L., Hangan, A. C., & Procopciuc, L. M. (2026) · Nutrients · doi:10.3390/nu18203382
Biological functions and emerging interplay of FGF21 and GDF15 in metabolic diseases and aging
Salmón‐Gómez, L., Keipert, S., Catalán, V., Rodrı́guez, A., Becerril, S., Frühbeck, G., & Gómez‐Ambrosi, J. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00627-w
Metadata
- Authors
- Fisher, F. M., Chui, P. C., Nasser, I. A., Popov, Y., Cunniff, J. C., Lundasen, T., Kharitonenkov, A., Schuppan, D., Flier, J. S., & Maratos-Flier, E.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Eli Lilly (United States) (US)
- Corresponding author
- Fisher, Ffolliott M.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2014-11
- Volume
- 147
- Issue
- 5
- Pages
- 1073-1083.e6
- ISSN
- 0016-5085 (ISSN-L)
- PMC
- PMC4570569
- OpenAlex
- W1984913749
- Cited by
- 263
- References
- 44
- Citations by year
- 2026: 14 · 2025: 14 · 2024: 13 · 2023: 21 · 2022: 25 · 2021: 32 · 2020: 28 · 2019: 24 · 2018: 20 · 2017: 21 · 2016: 30 · 2015: 17 · 2014: 2
- FWCI
- 9.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- FGF21, lipotoxicity, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, fatty acid beta-oxidation, hepatic steatosis, liver fibrosis, oxidative stress, free fatty acids, FGF21 knockout mice, high-fat diet
- MeSH terms
- Animals, Choline Deficiency, Disease Models, Animal, Fatty Acids, Fibroblast Growth Factors, Hepatitis, Liver, Liver Cirrhosis, Methionine, Mice, Inbred C57BL, Oxidation-Reduction, Recombinant Proteins, RNA, Messenger, Severity of Illness Index, Time Factors, Lipid Peroxidation, Mice, Knockout, Disease Progression, Inflammation Mediators, Infusions, Subcutaneous, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
